Silo Pharma Inc - Asset Resilience Ratio
Silo Pharma Inc (SILO) has an Asset Resilience Ratio of 36.22% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Silo Pharma Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Silo Pharma Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Silo Pharma Inc assets under control.
Liquid Assets Composition Over Time
This chart breaks down Silo Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Silo Pharma Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.16 Million | 36.22% |
| Total Liquid Assets | $2.16 Million | 36.22% |
Asset Resilience Insights
- Very High Liquidity: Silo Pharma Inc maintains exceptional liquid asset reserves at 36.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Silo Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Silo Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Silo Pharma Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Silo Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.75% | $2.11 Million | $7.61 Million | -15.09pp |
| 2024-12-31 | 42.83% | $3.17 Million | $7.41 Million | -10.62pp |
| 2023-12-31 | 53.46% | $4.14 Million | $7.75 Million | +53.43pp |
| 2022-12-31 | 0.03% | $3.12K | $11.64 Million | -3.98pp |
| 2021-12-31 | 4.00% | $420.00K | $10.49 Million | +3.99pp |
| 2020-12-31 | 0.01% | $200.00 | $1.43 Million | -80.42pp |
| 2017-12-31 | 80.43% | $1.32 Million | $1.64 Million | -- |
About Silo Pharma Inc
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's… Read more